Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David G Hicks

Showing results (81-90 of 132) with videos related to

Pageof 14
Sort By:
Human Pathology|November 18, 2023
HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low categoryCansu Karakas, Haley Tyburski, Bradley M Turner, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 2, 2015
Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence scoreBradley M Turner, Kristin A Skinner, Ping Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical courseBrian J Yoder, Elisa Tso, Marek Skacel, et al.
Archives of Pathology & Laboratory Medicine|April 4, 2023
Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein ExpressionGary Tozbikian, Savitri Krishnamurthy, Marilyn M Bui, et al.
Cancer Medicine|June 15, 2019
Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX<sup>®</sup> recurrence score <26Bradley M Turner, Mary Ann Gimenez-Sanders, Armen Soukiazian, et al.
Archives of Pathology & Laboratory Medicine|November 19, 2013
Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breastPatrick L Fitzgibbons, Deborah A Dillon, Randa Alsabeh, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 5, 2011
HER2 amplification, overexpression and score criteria in esophageal adenocarcinomaYingchuan Hu, Santhoshi Bandla, Tony E Godfrey, et al.
Journal of the National Cancer Institute|October 24, 2012
Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissuesVeronique M Neumeister, Valsamo Anagnostou, Summar Siddiqui, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 25, 2014
Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic timeMaria Vassilakopoulou, Fabio Parisi, Summar Siddiqui, et al.
Human Pathology|May 14, 2005
The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization studyDavid G Hicks, Brian J Yoder, James Pettay, et al.
Pageof 14

Showing results (81-90 of 132) with videos related to

Sort By:
Pageof 14
Human Pathology|November 18, 2023
HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low categoryCansu Karakas, Haley Tyburski, Bradley M Turner, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 2, 2015
Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence scoreBradley M Turner, Kristin A Skinner, Ping Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical courseBrian J Yoder, Elisa Tso, Marek Skacel, et al.
Archives of Pathology & Laboratory Medicine|April 4, 2023
Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein ExpressionGary Tozbikian, Savitri Krishnamurthy, Marilyn M Bui, et al.
Cancer Medicine|June 15, 2019
Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX<sup>®</sup> recurrence score <26Bradley M Turner, Mary Ann Gimenez-Sanders, Armen Soukiazian, et al.
Archives of Pathology & Laboratory Medicine|November 19, 2013
Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breastPatrick L Fitzgibbons, Deborah A Dillon, Randa Alsabeh, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 5, 2011
HER2 amplification, overexpression and score criteria in esophageal adenocarcinomaYingchuan Hu, Santhoshi Bandla, Tony E Godfrey, et al.
Journal of the National Cancer Institute|October 24, 2012
Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissuesVeronique M Neumeister, Valsamo Anagnostou, Summar Siddiqui, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 25, 2014
Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic timeMaria Vassilakopoulou, Fabio Parisi, Summar Siddiqui, et al.
Human Pathology|May 14, 2005
The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization studyDavid G Hicks, Brian J Yoder, James Pettay, et al.
Pageof 14